Fig. 1From: First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancerPlasma concentration-time curve ofBPI-9016M following continuous QD dosing. Average concentration-time curves for BPI-9016M, M1, and M2-2 in Chinese advanced NSCLC patients with single oral administration of 100–800 mg of BPI-9016M tabletBack to article page